Unilever and Geno launch $120m venture to scale alternative ingredients
- Using Geno’s cutting-edge biotechnology, the venture aims to commercialise and scale plant-based alternatives to feedstocks like palm oil, or fossil fuels, to make key ingredients used in everyday cleaning and personal care products.
- Unilever’s investment, which is the first to support the venture, also marks the company’s largest collaboration in biotechnology alternatives to palm oil to date.
- The venture is poised to offer a highly effective and sustainable alternative that can be offered to the combined $625b1 home and personal care markets.
LONDON, UK and SAN DIEGO, California - Today Unilever and Genomatica (Geno), a leader in biotech and sustainability, have launched a venture to scale and commercialise alternatives to palm oil and fossil fuel-derived cleansing ingredients. These are integral to the formulations of thousands of everyday cleaning and personal care products. With growing demand for sustainably-sourced palm oil, this venture aims to deliver additional responsibly sourced palm oil alternatives to the market.
With $120m jointly invested in the newly-formed initiative, and with other strategic investors expected to join, the venture will develop an alternative, plant-based ingredient using biotechnology. The innovation is particularly relevant to cleaning and personal care products that require ingredients to lather and lift dirt. But at present, there are few viable alternatives to palm and fossil sources that can be produced at scale in order to make those ingredients.
As such, the venture offers the opportunity to tap into the combined $625b home and personal care markets. For Unilever, one of the world’s biggest soap and detergent manufacturers, this is the largest investment in biotechnology alternatives to palm oil to date.
Companies like Unilever, whose products are used globally by 3.4b people each day, are increasingly partnering with biotechnology innovators like Geno to explore, develop, and manufacture new versions of traditionally-sourced ingredients. While palm oil will remain an important feedstock to Unilever, these alternative ingredients can play a growing role in diversifying supply chains to drive optionality, sustainability, cost efficiencies and transparency.
Geno will deploy its proven biotechnology platform and is already starting to scale the process for its advanced technology to produce the ingredients. Initial estimates have shown that companies could reduce the carbon footprint of palm-derived ingredients by up to 50% with this technology-driven, plant-based alternative.
Unilever’s Chief R&D Officer Richard Slater, said:
“Biotechnology has the potential to revolutionise the sourcing of our cleansing ingredients and ensure Unilever is a future-fit business – for consumers, shareholders and the planet we all share. This new venture will sit at the intersection of science and sustainability, meaning we can continue to grow our business without relying only on palm oil or fossil fuel derivatives, while also making our supply chains more resilient from having access to ingredient alternatives.
“We will be marrying science and nature to make sure there is no tradeoff for our consumers between the efficacy and sustainability of their products. We are building this innovative new venture to have the scale to drive real impact and change in our industry, helping to reinvent the chemistry of home and personal care products for the 21st Century.”
Christophe Schilling, Geno CEO said:
“Geno’s collaboration with Unilever builds upon its strong track record of partnering with market leaders who are committed to accelerating the commercialisation of sustainable materials in their industries – from clothing to now cleaning ingredients. We’ve developed our technology in response to our planet’s urgent climate crisis and we’ve proven that biotechnology can replace traditional production methods to produce ingredients with bio-based sources that deliver both high-performance and sustainability, at scale.
“Our technology enables pathways for alternative sourcing of materials whose supply chains often have limited social and environmental transparency, by offering more resilient supply chains that are transparent, traceable and responsibly-sourced, as demanded by consumers. Beyond creating new transparent and responsibly sourced-supply chains and alternatively-sourced materials, our Geno technology also represents the potential to reduce greenhouse gas emissions by 100 million tons in upcoming years.”
1 Source: Euromonitor
Geno is harnessing biology to remake everyday products and materials built by and for the planet. In response to the urgent climate crisis, Geno is developing and scaling sustainable materials derived from plant- or waste-based feedstocks instead of fossil fuels. Geno's technology, built over the last 20 years, now drives materials and ingredients in applications ranging from cosmetics, carpets, to home cleaners, apparel and more.
Geno uses the power of biotechnology to convert plant-based raw materials into chemical building blocks that are key components of widely used materials. Geno has developed a strong track record of partnering with market leaders including:
- Lululemon athletica (NASDAQ: LULU) on a multi-year collaboration with Geno to bring renewably-sourced, bio-based materials into lululemon’s products. This represents lululemon’s first-ever equity investment in a sustainable materials company and Geno’s largest partnership within the retail industry.
- Novamont to commercialise bio-based BDO at scale.
- Covestro AG (OTCMKTS: COVTY) to successfully produce significant volumes of a plant-based version HMDA, used in sustainable coatings.
- Asahi Kasei (OTCMKTS: AHKSY to commercialise renewably-sourced nylon 6,61 made from Geno’s bio-based HMD.
- Cargill-Helm (Qore) has licensed Geno’s BDO process technology and is using Cargill’s global feedstock supply and fermentation manufacturing expertise to initially produce and distribute an BDO at scale.
To learn more, visit genomatica.com
Where relevant, these actions are subject to the appropriate consultations and approvals.
This document may contain forward-looking statements, including ‘forward-looking statements’ within the meaning of the United States Private Securities Litigation Reform Act of 1995. Words such as ‘will’, ‘aim’, ‘expects’, ‘anticipates’, ‘intends’, ‘looks’, ‘believes’, ‘vision’, or the negative of these terms and other similar expressions of future performance or results, and their negatives, are intended to identify such forward-looking statements. Forward-looking statements also include, but are not limited to, statements and information regarding the Unilever Group’s (the ‘Group’) emissions reduction targets and other climate change related matters (including actions, potential impacts and risks associated therewith). These forward-looking statements are based upon current expectations and assumptions regarding anticipated developments and other factors affecting the Group. They are not historical facts, nor are they guarantees of future performance or outcomes.
Because these forward-looking statements involve risks and uncertainties, there are important factors that could cause actual results to differ materially from those expressed or implied by these forward-looking statements. Among other risks and uncertainties, the material or principal factors which could cause actual results to differ materially are: Unilever’s global brands not meeting consumer preferences; Unilever’s ability to innovate and remain competitive; Unilever’s investment choices in its portfolio management; the effect of climate change on Unilever’s business; Unilever’s ability to find sustainable solutions to its plastic packaging; significant changes or deterioration in customer relationships; the recruitment and retention of talented employees; disruptions in our supply chain and distribution; increases or volatility in the cost of raw materials and commodities; the production of safe and high quality products; secure and reliable IT infrastructure; execution of acquisitions, divestitures and business transformation projects; economic, social and political risks and natural disasters; financial risks; failure to meet high and ethical standards; and managing regulatory, tax and legal matters. A number of these risks have increased as a result of the current Covid-19 pandemic.
These forward-looking statements speak only as of the date of this document. Except as required by any applicable law or regulation, the Group expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Group’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based.
Further details of potential risks and uncertainties affecting the Group are described in the Group’s filings with the London Stock Exchange, Euronext Amsterdam and the US Securities and Exchange Commission, including in the Unilever Annual Report and Accounts 2021.